Analytical Data
-
Gene name
LASS2
- Application
-
Alternative Names
SP260; L3; TMSG1; CerS2; Longevity Assurance(LAG1)Homolog 2; Ceramide Synthase 2; LAG1 Longevity Assurance Homolog 2; Tumor Metastasis Suppressor Gene 1 Protein
-
Species
Human
-
Source
HEK293
-
Tag
N- His & C- Fc Region of Human IgG1
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96G23
-
Expression Region
Arg325~Asp380
-
Molecular Weight
38kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LASS2, or "Lipid-associated synthase 2," is a member of the LASS family, which plays a significant role in the biosynthesis of sphingolipids, critical components of cellular membranes that influence various biological processes. Research into LASS2 has gained momentum due to its potential implications in cancer biology and neurodegenerative diseases, where altered sphingolipid metabolism can contribute to disease progression. Initial studies suggested that LASS2 is involved in regulating apoptosis and cellular signaling pathways by modulating sphingolipid levels. Furthermore, its expression patterns are often altered in various cancer types, indicating its potential as a biomarker for tumor progression and as a therapeutic target. The recombinant expression of LASS2 permits detailed studies on its enzymatic properties and interactions with other cellular components, thereby enhancing our understanding of its biological functions. In light of its role in critical physiological and pathological processes, the investigation of LASS2 as a recombinant protein not only contributes to basic science but also holds promise for developing novel therapeutic strategies aimed at manipulating sphingolipid metabolism in disease contexts. Thus, ongoing research seeks to elucidate the precise mechanisms by which LASS2 operates and its influence on cellular homeostasis and disease states, paving the way for potential clinical applications.
